Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
1–10
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have participated in Protocol 328 (without discontinuation due to a study drug related AE).
Must sign an informed consent prior to initiating any stus dy procedures.
Have, in the opinion of the investigator, an on-going clinical indication for oral liquid formulation of candesartan cilexetil to control hypertension
Weight ≥ 10 kg and ≤ 40 kg.
You may not be if
Any situation, clinical condition (such as clinically significant declining renal function) or laboratory abnormality that, in the opinion of the investigator or sponsor, may interfere with the subject's participation in the study.
Estimated glomerular filtration rate (GFR) \<30 ml/min/1.73m2 for non-transplant patients and \<40 ml/min/1.73m2 for transplant patients based on the Schwartz Formula (Schwartz et al 1987) as determined at enrollment into Study 328.
Impaired liver function defined as either acute liver disease or chronic liver disease with persistently elevated liver enzyme values judged clinically significant by the investigator.
Currently using any medications that, in the opinion of the investigator could negatively affect the subject when given together with candesartan cilexetil.
Clareo Health | Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
